Page 3 - Text View News Today

SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the...

The U.S. Food and Drug Administration approved the use of IMBRUVICA for the treatment of pediatric patients one year and older with cGVHD after failure of one...

VILLEPINTE, France, June 13, 2022 /PRNewswire/ -- Guerbet (EuronextParis: GBT) (ISIN: FR0000032526), a global leader in medical imaging, announces today that Elucirem, the proposed Guerbet brand

Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and...

06.05.2022 - SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates.The study met its ...

SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular...

PALO ALTO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of...

Priority Review granted by US-FDA March 28, 2022

/PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and...

Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140...